Difference between revisions of "Neuroendocrine tumor"
Warner-admin (talk | contribs) m (Text replacement - "#eeee00" to "#91cf61") |
Warner-admin (talk | contribs) m (Text replacement - "cycles, given until progression of disease'''" to "cycles'''") |
||
Line 227: | Line 227: | ||
*[[Octreotide LAR (Sandostatin LAR)]] 30 mg IM once on day 1, with potentially higher doses if needed for symptom control | *[[Octreotide LAR (Sandostatin LAR)]] 30 mg IM once on day 1, with potentially higher doses if needed for symptom control | ||
− | '''28-day cycles | + | '''28-day cycles''' |
===Regimen #2 {{#subobject:925e2d|Variant=1}}=== | ===Regimen #2 {{#subobject:925e2d|Variant=1}}=== |
Revision as of 02:44, 29 December 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
This page is now exclusively focused on those tumors commonly called carcinoids, which may or may not be associated with the carcinoid syndrome; there are now separate pages for pancreatic NET and other endocrine cancers. Neuroendocrine tumors of unknown primary and poorly differentiated (high-grade) neuroendocrine tumors are usually treated with a small cell lung cancer regimen.
14 regimens on this page
20 variants on this page
|
Guidelines
ESMO
- Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
- Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
NCCN
All lines of therapy
Everolimus monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy | Toxicity |
---|---|---|---|---|
Yao et al. 2015 (RADIANT-4) | Phase III | Placebo | Superior PFS | Equivalent HRQoL |
Chemotherapy
- Everolimus (Afinitor) 10 mg PO once per day
Given until progression of disease, unacceptable toxicity, drug interruption of 3 weeks or longer, or withdrawal of consent
References
- Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977. Epub 2015 Dec 17. link to original article contains protocol PubMed
- HRQoL analysis: Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1411-1422. Epub 2017 Aug 30. link to original article PubMed
Interferon alfa-2b monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Faiss et al. 2003 | Phase III | Lanreotide | Seems not superior |
Lanreotide & Interferon alfa-2b | Seems not superior |
Immunotherapy
- Interferon alfa-2b (Intron-A) 5 million units SC given once per day, 3 times per week
Given until progression of disease
Patients who progressed on monotherapy then received combination lanreotide & interferon alfa.
References
- Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003 Jul 15;21(14):2689-96. link to original article contains verified protocol PubMed
Lanreotide monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Faiss et al. 2003 | Phase III | Interferon alfa-2b | Seems not superior |
Lanreotide & Interferon alfa-2b | Seems not superior |
Endocrine therapy
- Lanreotide (Somatuline) 1 mg SC TID
Given until progression of disease
Patients who progressed on monotherapy then received combination lanreotide & interferon alfa.
References
- Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003 Jul 15;21(14):2689-96. link to original article contains verified protocol PubMed
Lanreotide & Interferon alfa-2b
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Faiss et al. 2003 | Phase III | Interferon alfa-2b | Seems not superior |
Lanreotide | Seems not superior |
Endocrine & Immunotherapy
- Lanreotide (Somatuline) 1 mg SC TID
- Interferon alfa-2b (Intron-A) 5 million units SC given once per day, 3 times per week
References
- Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003 Jul 15;21(14):2689-96. link to original article contains verified protocol PubMed
Octreotide monotherapy
back to top |
Regimen #1
Study | Evidence |
---|---|
Oberg et al. 2004 | Consensus guideline |
Endocrine therapy
- Octreotide (Sandostatin) 0.1 to 0.5 mg SC given 2 to 4 times per day, with dose increased by doubling the dose every 3 to 4 days as needed to control symptoms
- "A reasonable starting dose is" 0.15 mg SC TID
Treatment continued indefinitely unless patients have unmanageable side-effects or insufficient control of symptoms
Regimen #2
Study | Evidence |
---|---|
Kvols et al. 1986 | Phase II |
Endocrine therapy
- Octreotide (Sandostatin) 0.15 mg SC BID on days 1 & 2, then 0.15 mg TID on days 3 and on
"Treatment was continued for as long as a clinical improvement was maintained"
Regimen #3
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Kölby et al. 2003 | Randomized Phase II | Octreotide & Interferon alfa | Inferior TTP |
Endocrine therapy
- Octreotide (Sandostatin) 0.1 mg SC BID; patients with persistent carcinoid symptoms could receive increased doses up to 0.2 mg SC TID
References
- Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663-6. link to original article contains verified protocol PubMed
- Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32(2):225-9. link to original article PubMed
- Kölby L, Persson G, Franzén S, Ahrén B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003 Jun;90(6):687-93. link to original article contains verified protocol PubMed
- Review: Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004 Jun;15(6):966-73. link to original article contains verified protocol PubMed
Octreotide LAR monotherapy
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Rinke et al. 2009 (PROMID) | Phase III | Placebo | Superior TTP |
Pavel et al. 2011 (RADIANT-2) | Phase III | Octreotide LAR & Everolimus | Seems to have inferior PFS |
Endocrine therapy
- Octreotide LAR (Sandostatin LAR) 30 mg IM once on day 1, with potentially higher doses if needed for symptom control
28-day cycles
Regimen #2
Study | Evidence |
---|---|
Oberg et al. 2004 | Consensus guideline |
Endocrine therapy
- Octreotide LAR (Sandostatin LAR) 20 to 30 mg IM once on day 1, with potentially higher doses if needed for symptom control
- "As a general rule, if the total [octreotide] IR dose is 200 to 600 mcg/day [0.2 to 0.6 mg/day], LAR 20 mg should be tried, and if total IR dose is 750 to 1500 mcg/day [0.75 to 1.5 mg/day], LAR 30 mg should be tried."
- Octreotide (Sandostatin) (dose not specified) SC as needed for additional symptom control
28-day cycles; treatment continued indefinitely unless patients have unmanageable side-effects or insufficient control of symptoms
References
- Review: Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004 Jun;15(6):966-73. link to original article contains verified protocol PubMed
- Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. Epub 2009 Aug 24. link to original article contains verified protocol PubMed
- Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10;378(9808):2005-12. Epub 2011 Nov 25. link to original article contains verified protocol PubMed
Octreotide & Everolimus
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Pavel et al. 2011 (RADIANT-2) | Phase III | Octreotide LAR | Seems to have superior PFS |
Endocrine & Chemotherapy
- Octreotide LAR (Sandostatin LAR) 30 mg IM once every 28 days
- Everolimus (Afinitor) 10 mg PO once per day
Given until progression of disease or unacceptable toxicity
Regimen #2
Study | Evidence |
---|---|
Yao et al. 2008 | Phase II |
Note: Everolimus "dose of 10 mg was associated with superior PFS...however, the study was not prospectively powered for these comparisons. These analyses should be considered exploratory."
Endocrine & Chemotherapy
- Octreotide LAR (Sandostatin LAR) 30 mg IM once on day 1
- Everolimus (Afinitor) 5 or 10 mg PO once per day on days 1 to 28
28-day cycle for up to 12 cycles or until progression of disease, though treatment could be continued beyond this period if thought by the treating physician to be beneficial
References
- Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10;26(26):4311-8. link to original article contains verified protocol link to PMC article PubMed
- Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10;378(9808):2005-12. Epub 2011 Nov 25. link to original article contains verified protocol PubMed
Octreotide & Interferon alfa
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Kölby et al. 2003 | Randomized Phase II | Octreotide LAR | Superior TTP |
Kölby et al. 2003 did not specifically say whether Interferon alfa-2b (Intron-A) or Interferon alfa-2a (Roferon-A) was used.
Endocrine & Immunotherapy
- Octreotide (Sandostatin) 0.1 mg SC BID; patients with persistent carcinoid symptoms could receive increased doses up to Octreotide (Sandostatin) 0.2 mg SC TID
- Interferon alfa-2b (Intron-A) 3 million units (route not specified) given once per day, 3 days per week; increased as needed based on symptoms up to Interferon alfa-2b (Intron-A) 5 million units (route not specified) given once per day, 5 days per week
References
- Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32(2):225-9. link to original article PubMed
- Kölby L, Persson G, Franzén S, Ahrén B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003 Jun;90(6):687-93. link to original article contains verified protocol PubMed
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Rinke et al. 2009 (PROMID) | Phase III | Octreotide LAR | Inferior TTP |
No active antineoplastic treatment. Used as a comparator arm and here for reference purposes only.
References
- Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. Epub 2009 Aug 24. link to original article contains verified protocol PubMed
Temozolomide monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Ekeblad et al. 2007 | Phase II |
Chemotherapy
- Temozolomide (Temodar) as follows:
- Cycle 1: 100 or 150 mg/m2 PO once per day on days 1 to 5
- Cycle 2 onwards: increased as tolerated up to 200 mg/m2 PO once per day on days 1 to 5
Supportive medications
- Tropisetron (Navoban) (dose/route/schedule not specified) routinely used as an antiemetic
28-day cycles, given until progression of disease or unacceptable toxicity
References
- Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007 May 15;13(10):2986-91. link to original article contains verified protocol PubMed